Isaac Asante, PhD, is a translational scientist who combines expertise from pharmacology, metabolomics/lipidomics, and biomedical engineering to develop novel interventions for inflammatory and neurodegenerative conditions. Dr. Asante has conducted preclinical and clinical development of novel interventions that have had an impact on millions of lives across the world. Early in his research career, he partnered with industry to produce the maiden malaria vaccine. Later, he focused his efforts on using novel biomarkers for cancer and other inflammatory conditions. He researched the role of folate one-carbon metabolism in patients who developed colorectal cancer, reviewed a previously unknown metabolic pathway. Most recently, he used a novel renin-angiotensin system (RAS) metabolomics to probe mechanistic processes that underlie various inflammatory and neurodegenerative diseases. In addition, he was able to develop and validate a lipidomic test that can serve as an accurate “liquid biopsy” of patients with inflammatory and neurodegeneration. These “omics” developments were able to guide intervention development and differentiate various types of age-related macular degeneration (AMD), retinitis pigmentosa, and traumatic brain injury. His efforts have spanned from developing interventions for traumatic brain injury to developing novel therapeutics to address ophthalmic regeneration of cornea and preservation of the retina. Dr. Asante also develops biomarkers and models them into predictive algorithms for diagnosis, prognosis, and therapeutic monitoring. Such models have been used in acute respiratory distress syndrome and colorectal cancer. Dr. Asante joined the USC Roski Eye institute in 2020, as an Assistant Professor of Research.